AbbVie to sell Allergan Biologics to Pharmaron for $119 million

  • Hong Kong-listed R&D service provider, Pharmaron Beijing has agreed to acquire Allergan Biologics Limited for $118.7M in cash from AbbVie (NYSE:ABBV).
  • Subject to customary closing conditions, the transaction is expected to close in Q2 2021. With over 150 staff, ABL has built its expertise in Cell and Gene Therapy (“CGT”) product development using a suspension system for manufacturing, a statement from Pharmaron said.
  • ABL consisting of a flexible cGMP biomanufacturing facility located in Liverpool, UK ‘will further strengthen our CGT services platform and allow us to better serve our partners’ needs in these exciting and emerging therapies,’ commented Boliang Lou CEO of Pharmaron.
  • In January, AbbVie-owned Allergan Aesthetics announced a warrant agreement to acquire the privately-held medical device firm Cypris Medical.

    Abbvie fundamentals

    Over the current book year the company from North Chicago could achieve a revenue around 55.36 billion USD (consensus estimates). This is rather significant more than 2020's revenue of 45.8 billion USD.

    Historical revenues and results Abbvie plus estimates 2020

    financiële analyse Abbvie

    The analysts expect for 2021 a net profit of 22.12 billion USD. According to most of the analysts the company will have a profit per share for this book year of 12.43 USD. So the price/earnings-ratio equals 8.58.

    Huge dividend Abbvie

    Per share the analysts anticipate on a dividend of 5.13 USD per share. Thus the dividend yield equals 4.81 percent. The average dividend yield of the biotech companies is a limited 0.37 percent.

    Based on the current number of shares Abbvie 's market capitalization equals 157.8 billion USD. The Abbvie stock was the past 12 months quite volatile. Since last March the stock is even 26 percent higher. This year the stock price moved between 63 and 113 dollar.

    Historical stock prices Abbvie past 10 years

    equity research abbvie

    Click here for dividend Abbvie. On Friday, the stock closed at 106.7 USD.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.

    • Other stock news
    Currently quite high dividend Abbvie
    Analysts expect over 2021 rising revenue Abbvie, relatively high dividend
    Analysts expect over 2021 rising revenue Abbvie, quite high dividend
    Analysts: more sales Abbvie, huge dividend
    AbbVie in talks to sell $5B women's drugs portfolio
    Analysts expect over 2020 rising revenue Abbvie, relatively high dividend
    Analysts foresee more revenue Abbvie, huge dividend
    Sector news
    Analysts estimate for 2023 rising sales Sartorius
    Currently quite high dividend Abbvie
    Analysts expect over 2023 growing sales Biocartis
    Analysts expect over 2023 shrinking sales Galapagos
    Analysts expect over 2023 decreasing revenue arGEN-X
    Analysts expect over 2023 revenue increase Biocartis
    Analysts: this year best year ever for Amgen
    National news
    Analysts expect record sales Lockheed Martin
    Analysts: more sales Halliburton
    Fiserv's sales on record level according analysts' estimates
    Intuitive Surgical's sales on record level according analysts' estimates
    Analysts are counting on record year NetFlix
    Analysts expect record sales CSX
    Analysts expect sales decline Carmax
    Press news
    Schweizer Electronic AG: Expansion of the Executive Board – Appointment of Mr. Thomas Gottwald as new member of the Executive Board
    q.beyond supports introduction of SAP S/4HANA at Neue Westfälische with its applications expertise
    NorCom wins tender from the Federal Employment Agency for Business Intelligence Platform
    HHLA acquires interest in Austrian intermodal service provider Roland Spedition GmbH
    audius publishes its annual report for 2023 and proposes a dividend of 35 cents per share (news with additional features)
    OHB SE: Consolidated financial statements 2023
    Mayr-Melnhof Karton AG: MM reports first quarter 2024 results
    Logoanalist
    Returns European stocks
    Crypto currencies information
    About us Network Partners
    Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos Analist.nlLinksISIN
  • Glossary
    		• MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-xBats
    ©2024 ValueSpectrum. All Rights Reserved
    Developed and maintained by  Velainn logo